Clinical Core

全球健康的营养、感染和癌症护理点技术(征兆) 4.0临床翻译和验证核心 摘要 临床翻译和验证核心是预兆的独特优势-已被 通过领导层多年的能力建设建立起来的。由独一无二的 在纽约、乌干达、厄瓜多尔和印度的全球合作伙伴临床站点网络，该网络将 提供更广泛的临床人群、临床和社区专业知识， 和生物库，而不是PoC开发人员目前可以访问的。核心已经被构造成 响应中心的需求，使我们能够将资金和资源分配到临床支持的站点 与项目的验证和培训需求最匹配。每个站点将有一个基准预算，以 促进当地能力建设，目标是进一步将其打造为公认的全球中心 在提议的工作结束之前，在PoC诊断验证方面的卓越表现。核心将集中在四个方面 主要目标：(1)开发预兆中心和POCTRN网络，以实现人类和临床验证 通过提供对大量样本生物库和独特患者的访问，提供护理点(PoC)技术 人口，(2)支持项目进行的验证研究的设计(包括统计支持) 团队，(3)与技术核心合作，确定可以过渡到的新的和现有的PoC项目 人类验证和传播核心，以制定年度需求评估共识，以及(4) 为开发人员临床轮换提供访问站点。这个临床网络的建立将是 对全球健康PoC设备的开发和转换具有变革性，因为它将 大大降低了开发人员将他们的技术瞄准这一更广泛的集合的门槛 人口。正如我们在需求评估中所指出的那样，LMIC中的患者是世界上最脆弱的群体之一 和位于PoC技术可产生最大影响的位置。预兆的成功可能 显著改善这些地区的当地健康状况。

Point of Care Technologies for Nutrition, Infection and Cancer for Global Health (PORTENT) 4.0 Clinical Translation and Validation Core Abstract The Clinical Translation and Validation Core is a unique differentiator for PORTENT – one that has been established through many years of capacity building by the leadership. Consisting of a one-of-a-kind worldwide network of partner clinical sites in New York, Uganda, Ecuador and India, this network will provide access to a much more diverse range of clinical populations, clinical and community expertise, and biobanks than are currently accessible to PoC developers. The core has been structured to be responsive to the needs of the center, allowing us to allocate funds and resources to sites where clinical support is best matched to the validation and training needs of the projects. Each site will have a baseline budget to enable local capacity building with the goal of further establishing them as recognized worldwide centers of excellence in PoC diagnostic validation before the end of the proposed effort. The core will focus on four main goals: (1) to enable human and clinical validation of PORTENT center and POCTRN network developed Point-of-Care (PoC) technologies by providing access to a wide array of sample biobanks and unique patient populations, (2) to support the design (including statistical support) of validation studies conducted by the project teams, (3) to work with the Tech Core to identify new and existing PoC projects which can be transitioned to human validation and the Dissemination Core to develop the annual needs assessment consensus, and (4) to provide access sites for developer clinical rotations. The establishment of this clinical network will be transformative to the development and translation of PoC devices for global health because it will significantly lower the barriers for developers to target their technologies to this broader set of populations. As noted in our needs assessment, patients in LMICs are some of the most vulnerable in the world and are located where access to PoC technology could have the highest impact. Success with PORTENT could significantly improve local health outcomes in these areas.